Hughes Report: First Anniversary

Luke Evans Excerpts

Thursday 27th March 2025 Westminster Hall

[Dr Luke Evans (Hinckley and Bosworth) (Con)]

It is a pleasure to serve under your stewardship, Ms Furniss. As a GP who has seen patients with valproate and mesh injuries, standing here with a chance to raise this issue is humbling for me.

I am grateful to the hon. Member for Washington and Gateshead South (Mrs Hodgson) for proposing this debate. It is yet another important topic that she has brought to the House. She is in danger of rivalling the hon. Member for Strangford (Jim Shannon) for securing so many Westminster Hall debates on health. The fact that we have two worthy champions fighting it out to be the person in the country doing the most for health is a true testament to the dynamics we have; I congratulate the hon. Member for Washington and Gateshead South on that. I remember her powerful contributions to last month’s Westminster Hall debate on women’s health, and she has done the same today. With her personal experience of her mother’s situation, and as the chair of the APPG first do no harm, she is a true champion.

Now that we are past the first anniversary of the Hughes report, this debate is an important opportunity for the women and families affected by valproate and pelvic mesh to get clarity from the Government on what progress is being made on the recommendations of the report and a way forward more broadly. It is heartening to see how the Chamber has come together to ask unanimously for that progress. I welcome the fact that the previous Government took productive steps and asked the Patient Safety Commissioner, Dr Henrietta Hughes, to undertake work in this area. Her report was issued a year ago, and it is clear that the victims are anxious for some form of redress for the harms that have been caused. The report states:

“The first point to make clear is that the Commissioner thinks that there is a clear case for redress based on the systemic healthcare and regulatory failures revealed by the First Do No Harm review in 2020. The Commissioner supports a restorative practice-based redress scheme, co-designed with affected patients, and which is, therefore, very different from court proceedings which seek to attribute blame.”

Of course an election halts progress, but now, with new Ministers and a new Government nine months in, it is right to continue keeping the spotlight on this topic. To that end, my questions echo many of those raised by others. Could the Minister clarify the Government’s position on the recommendation for financial redress, and could she give a timeframe for when they will respond to the report? Has the Minister met with Dr Hughes and campaigners to discuss the report, and will she commit to communicating with all those affected, as that is so important to help reduce some of the anxiety? It has already been a long and painful journey for victims, so continuing to take steps forward to address the fallout is important.

Further to the Hughes report, I am glad that the last Government took several actions to begin addressing the injustices suffered by victims of valproate and pelvic mesh. The former Health Secretary, my right hon. Friend the Member for Godalming and Ash (Jeremy Hunt), established the Cumberlege review, and significant progress was rightly made before the election on implementing seven of Dr Hughes’s recommendations. Those included an unreserved apology to the women and children affected, and their families, on behalf of the healthcare system, for the time the system took to listen and respond. I am pleased to see that the hon. Member for Gorton and Denton (Andrew Gwynne), the new Minister at the time, reiterated that apology when these issues were last debated in December 2024. Progress also included the appointment of Dr Hughes as the first Patient Safety Commissioner to advocate for patients and improve the safety of medicines and medical devices, and a network of specialist centres established to provide comprehensive treatment, care and advice for those affected by implanted mesh.

Hon. Members have already referenced the Westminster Hall debate on these issues last December. Looking at the record of that debate, I was pleased to see from the hon. Member for Gorton and Denton that the Government were committed to implementing the remaining three recommendations as a priority. He said:

“It is a priority for this Government. We are working at pace, and we remain focused on making meaningful progress. This is a complex area of work, involving several Departments, but we are committed to providing an update at the earliest opportunity. I have heard the desire for urgency today, and I hope that we can make the progress that Members want to see.”—[Official Report, 5 December 2024; Vol. 758, c. 175WH.]

I know that there has been a change in personnel in the ministerial team since that debate, but can the Minister confirm that it remains a priority for the Government regardless? Given that it is now four months since the last debate, and the Minister recognises the desire for urgency, what new update can she provide on the progress that has been made in implementing these recommendations since December?

As stated, I was in the debate on women’s health last month, in which the hon. Member for Washington and Gateshead South raised the issue. The Minister’s response was:

“On sodium valproate and pelvic mesh, the Cumberlege review made nine recommendations, of which the then Government accepted seven. I can confirm that the national pause remains in place.”—[Official Report, 27 February 2025; Vol. 762, c. 518WH.]

I also note that the Minister frequently quotes the following lines in her response to written parliamentary questions from colleagues:

“The Government will be providing an update to the Patient Safety Commissioner’s Report at the earliest opportunity.”

So could she say whether today is “the earliest opportunity”? If it is not, would she be kind enough to give an estimate of when that might be?

During that December debate, the shadow Minister, my hon. Friend the Member for Sleaford and North Hykeham (Dr Johnson), also raised concerns about the experiences of some of the women within the specialist mesh centres, and urged Ministers to look into that. I would be grateful if the Minister could set out whether she shares those same concerns. If so, what steps has her Department taken to address these and look into them?

Finally on sodium valproate, we have heard from my hon. Friend the Member for Harrow East (Bob Blackman) and the hon. Member for Bexleyheath and Crayford (Daniel Francis) about the difficulty we have when it comes to valproate, given the damage it can cause but its importance as an epilepsy drug in supporting people to keep seizure free. The report itself states:

“However, the Commissioner continues to have concerns about incomplete adherence to the Pregnancy Prevention Programme requirements. As a result, in November 2023, she recommended that NHS England create a fully funded and resourced system for improving the safe use of the most potent teratogenic medications, beginning with the safe use of valproate.”

With that being said, could the Minister update this House on the workstream regarding teratogenic medications? More importantly, given the news of the abolition of NHS England, what safeguards are being put in place to ensure that this system is resourced adequately?

“One year on” is a milestone to be celebrated—for getting this far after such a torrid journey in raising concerns, having them heard and getting them responded to—but it is just that: a milestone on a journey, not a destination. For those so affected, and their families, they will be keen to know what redress they are due and the mechanisms to deliver it, so that their cases might finally be fully rectified. After all, we cannot undo the past, but we can make amends for it, and I hope that the Government will continue to act on the recommendations to do so.